Continuing an R&D revamp, GlaxoSmithKline hands off its rare disease unit to Orchard Therapeutics
GlaxoSmithKline couldn’t find a buyer for their gene therapy unit, but they did find a taker.
GSK said this morning that it has lateraled off …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
